Health technology appraisals have yielded mixed results for CAR-T therapies in Scotland as the Scottish Medicines Consortium said yes to Novartis’ Kymriah (tisagenlecleucel) but no to Gilead’s Yescarta (axicabtagene ciloleucel). In response to the decisions, a research charity warned that while CAR-T therapies could be game changing treatments, the high prices they command would be a reoccurring issue.
The SMC has declined to recommend Yescarta for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma, following at least two lines of systemic therapy
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?